🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 09/08/2018 | 175,74 | 177,45 | 174,95 | 175,05 | -0,14% | 1,42% | 837.000 |
| 08/08/2018 | 177,25 | 178,40 | 175,25 | 175,30 | -1,25% | 1,78% | 903.500 |
| 07/08/2018 | 175,94 | 178,00 | 175,48 | 177,51 | +1,49% | 1,43% | 1.097.800 |
| 06/08/2018 | 175,55 | 175,99 | 173,26 | 174,91 | +0,21% | 1,56% | 761.500 |
| 03/08/2018 | 174,20 | 178,09 | 173,76 | 174,54 | -1,88% | 2,49% | 1.118.000 |
| 02/08/2018 | 174,59 | 179,86 | 173,51 | 177,89 | +0,01% | 3,64% | 1.684.300 |
| 01/08/2018 | 175,26 | 177,93 | 174,04 | 177,87 | +1,61% | 2,22% | 1.384.500 |
| 31/07/2018 | 175,05 | 175,74 | 173,58 | 175,05 | +0,36% | 1,23% | 1.529.400 |
| 30/07/2018 | 170,65 | 175,34 | 169,97 | 174,42 | +1,35% | 3,15% | 1.534.200 |
| 27/07/2018 | 175,18 | 176,29 | 169,52 | 172,10 | -2,14% | 3,86% | 1.392.100 |
| 26/07/2018 | 178,61 | 178,85 | 169,33 | 175,87 | -0,53% | 5,33% | 2.400.700 |
| 25/07/2018 | 174,78 | 177,42 | 173,99 | 176,81 | +1,10% | 1,96% | 1.524.500 |
| 24/07/2018 | 178,44 | 178,67 | 174,39 | 174,88 | -0,94% | 2,40% | 1.705.000 |
| 23/07/2018 | 176,29 | 178,67 | 176,16 | 176,54 | -0,48% | 1,42% | 1.388.700 |
| 20/07/2018 | 180,12 | 180,14 | 176,71 | 177,40 | -1,51% | 1,90% | 1.606.400 |
| 19/07/2018 | 180,13 | 180,93 | 178,52 | 180,12 | -0,56% | 1,34% | 1.080.500 |
| 18/07/2018 | 182,00 | 182,34 | 180,58 | 181,13 | -0,80% | 0,97% | 1.138.500 |
| 17/07/2018 | 180,58 | 183,39 | 179,82 | 182,59 | +0,76% | 1,98% | 1.133.000 |
| 16/07/2018 | 179,85 | 182,41 | 179,55 | 181,22 | +0,40% | 1,59% | 1.961.500 |
| 13/07/2018 | 178,35 | 181,60 | 177,90 | 180,50 | +1,25% | 2,07% | 1.457.300 |
| 12/07/2018 | 175,02 | 178,33 | 175,02 | 178,27 | +1,86% | 1,89% | 1.181.100 |
| 11/07/2018 | 173,83 | 175,69 | 173,00 | 175,01 | -0,06% | 1,55% | 1.618.400 |
| 10/07/2018 | 174,91 | 175,71 | 172,95 | 175,11 | +0,55% | 1,58% | 1.600.000 |
| 09/07/2018 | 174,37 | 174,62 | 171,81 | 174,16 | +0,41% | 1,61% | 1.334.700 |
| 06/07/2018 | 170,00 | 173,64 | 169,42 | 173,45 | +2,34% | 2,48% | 1.518.900 |
| 05/07/2018 | 168,38 | 169,95 | 166,71 | 169,49 | +1,05% | 1,92% | 1.178.600 |
| 03/07/2018 | 170,00 | 170,00 | 167,28 | 167,73 | -1,11% | 1,60% | 1.059.900 |
| 02/07/2018 | 168,40 | 169,66 | 164,70 | 169,61 | -0,21% | 2,95% | 2.283.600 |
| 29/06/2018 | 161,50 | 172,00 | 161,50 | 169,96 | +15,16% | 6,50% | 6.716.400 |
| 28/06/2018 | 147,79 | 148,52 | 145,37 | 147,59 | +0,06% | 2,13% | 1.368.400 |